IL314334A - Pharmaceutical composition including phthalazinone derivative for co-administration with anticancer drug - Google Patents

Pharmaceutical composition including phthalazinone derivative for co-administration with anticancer drug

Info

Publication number
IL314334A
IL314334A IL314334A IL31433424A IL314334A IL 314334 A IL314334 A IL 314334A IL 314334 A IL314334 A IL 314334A IL 31433424 A IL31433424 A IL 31433424A IL 314334 A IL314334 A IL 314334A
Authority
IL
Israel
Prior art keywords
pharmaceutical composition
combination
cancer
administration
drug
Prior art date
Application number
IL314334A
Other languages
English (en)
Hebrew (he)
Original Assignee
Idience Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idience Co Ltd filed Critical Idience Co Ltd
Publication of IL314334A publication Critical patent/IL314334A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL314334A 2022-01-25 2023-01-25 Pharmaceutical composition including phthalazinone derivative for co-administration with anticancer drug IL314334A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263302834P 2022-01-25 2022-01-25
PCT/IB2023/000030 WO2023144626A1 (en) 2022-01-25 2023-01-25 Pharmaceutical composition including phthalazinone derivative for co-administration with anticancer drug

Publications (1)

Publication Number Publication Date
IL314334A true IL314334A (en) 2024-09-01

Family

ID=87470837

Family Applications (1)

Application Number Title Priority Date Filing Date
IL314334A IL314334A (en) 2022-01-25 2023-01-25 Pharmaceutical composition including phthalazinone derivative for co-administration with anticancer drug

Country Status (14)

Country Link
US (1) US20250120970A1 (cg-RX-API-DMAC7.html)
EP (1) EP4469051A4 (cg-RX-API-DMAC7.html)
JP (1) JP2025505381A (cg-RX-API-DMAC7.html)
KR (1) KR20240138069A (cg-RX-API-DMAC7.html)
CN (1) CN118613264A (cg-RX-API-DMAC7.html)
AU (1) AU2023210923A1 (cg-RX-API-DMAC7.html)
CA (1) CA3249330A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024002218A1 (cg-RX-API-DMAC7.html)
IL (1) IL314334A (cg-RX-API-DMAC7.html)
JO (1) JOP20240162A1 (cg-RX-API-DMAC7.html)
MA (1) MA66598A1 (cg-RX-API-DMAC7.html)
MX (1) MX2024009168A (cg-RX-API-DMAC7.html)
TW (1) TW202339753A (cg-RX-API-DMAC7.html)
WO (1) WO2023144626A1 (cg-RX-API-DMAC7.html)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102372706A (zh) * 2010-08-09 2012-03-14 江苏恒瑞医药股份有限公司 酞嗪酮类衍生物、其制备方法及其在医药上的应用
EP2833883A4 (en) * 2012-04-06 2015-12-23 Indus Pharmaceuticals Inc NOVEL COMPOSITIONS OF COMBINATIONS OF NONCOVALENT DNA BINDER AND CANCER-INHIBITING AND / OR INFLAMMATORY ACTIVE SUBSTANCES AND THEIR USE IN THE TREATMENT OF ILLNESSES
KR101670126B1 (ko) * 2013-09-13 2016-10-27 일동제약(주) 신규 프탈라지논 유도체 및 그 제조방법
US12036222B2 (en) * 2018-04-04 2024-07-16 The Wistar Institut of Anatomy and Biology Methods of treating cancers overexpressing CARM1 with EZH2 inhibitors and a PARP inhibitor
WO2021214502A1 (en) * 2020-04-21 2021-10-28 Idience Co., Ltd. Process for preparing a phthalazinone derivative and intermediates thereof
KR102913343B1 (ko) * 2020-04-21 2026-01-15 아이디언스 주식회사 프탈라지논 화합물의 결정형

Also Published As

Publication number Publication date
TW202339753A (zh) 2023-10-16
CA3249330A1 (en) 2023-08-03
MX2024009168A (es) 2024-08-09
JP2025505381A (ja) 2025-02-26
EP4469051A1 (en) 2024-12-04
KR20240138069A (ko) 2024-09-20
CN118613264A (zh) 2024-09-06
MA66598A1 (fr) 2024-11-29
CL2024002218A1 (es) 2024-12-20
WO2023144626A1 (en) 2023-08-03
EP4469051A4 (en) 2025-12-17
AU2023210923A1 (en) 2024-07-25
US20250120970A1 (en) 2025-04-17
JOP20240162A1 (ar) 2024-07-23

Similar Documents

Publication Publication Date Title
IL255148B (en) 1901 rad for use in a method to inhibit a cancerous growth or induce tumor regression in a patient who is resistant to the drug and/or has cancer positive for an estrogen receptor alpha mutation
NZ551406A (en) Treatment of non small cell lung cancer with gemcitabine and erlotinib (an egfr kinase inhibitor)
US20160074390A1 (en) Human dosing of phosphatase inhibitor
AU2013299841A1 (en) Pharmaceutical combinations comprising a B-Raf inhibitor, an EGFR inhibitor and optionally a PI3K-alpha inhibitor
IL322021A (en) Methods for treating small cell lung cancer using lorbinectadine formulations
US20230255946A1 (en) Methods of treating diseases and disorders with deupirfenidone
NZ551431A (en) Treatment with cisplatin and an EGFR-inhibitor
IL253048B2 (en) A pharmaceutical preparation for the treatment of cancer containing a lactate metal salt
IL311682A (en) Methods for treating chronic kidney disease with dapagliflozin
IL279208B2 (en) Therapeutic methods and compositions for treating pancreatic cancer using 6, 8-bis(benzylsulfonyl)octanoic acid
TW202302084A (zh) 以安森司坦和帕博西尼治療乳癌
IL297043A (en) Drug combination including tno155 and nazaretinib
IL298071A (en) Treatment of breast cancer using combination therapies comprising gdc-9545 and a cdk4/6 inhibitor
IL298538A (en) Methods of treating her2 positive cancer with tucatinib in combination with trastuzumab and an oxaliplatin-based chemotherapy
IL301293A (en) Methods and compositions containing a KRASG12C inhibitor and a VEGF inhibitor for the treatment of solid tumors
IL294647A (en) AHR inhibitors and their uses
NZ551355A (en) Treatment of cancer with irinotecan (CPT-11) and erlotinib
US20220125792A1 (en) Use of composition containing cdk4/6 inhibitor in combination with anastrozole in preparation of medicament for treating tumor diseases
IL296196A (en) Methods of administering elagolix
US20250120970A1 (en) Pharmaceutical composition including phthalazinone derivative for co-administration with anticancer drug
IL321150A (en) Pharmaceutical composition for prevention or treatment of drug-related peptic ulcer comprising zastaprazan or pharmaceutically acceptable salt thereof
IL322387A (en) Methods for reducing the risk of major adverse cardiovascular events among subjects in primary prevention
TW202237078A (zh) 使用德弗米司特(devimistat)治療肉瘤之治療方法及組合物
IL292982A (en) Methods of Administering Voxlotor
HK40111558A (en) Pharmaceutical composition including phthalazinone derivative for co-administration with anticancer drug